menu
    • menu
    [{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Omega-3","moa":"PPAR gamma","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Grace Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Grace Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"DS Biopharma","sponsor":"Nuvothera","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Omega-3","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"DS Biopharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical cream","sponsorNew":"DS Biopharma \/ Nuvothera","highestDevelopmentStatusID":"12","companyTruncated":"DS Biopharma \/ Nuvothera"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Omega-3","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Omega-3","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"NovaBay Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"NovaBay Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Omega-3

    Menu

    Omega-3

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3,Maqui Berry Extract

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Launches Avenova Bundles for Multifactorial Dry Eye Relief

                            Details : Avenova is a nutrient-rich, antioxidantdense extract of the superfruit maqui berry, and high quality, natural triglyceride omega-3 oils to comfort dry eyes and support overall eye health.

                            Product Name : Avenova

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 13, 2024

                            Lead Product(s) : Omega-3,Maqui Berry Extract

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            NovaBay Pharmaceuticals

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3,Maqui Berry Extract

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NovaBay Pharmaceuticals Launches Avenova® Eye Health Support, a New Antioxidant-Rich Oral Supplement to Comfo...

                            Details : Avenova is a nutrient-rich, antioxidantdense extract of the superfruit maqui berry, and high quality, natural triglyceride omega-3 oils to comfort dry eyes and support overall eye health.

                            Product Name : Avenova

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 07, 2023

                            Lead Product(s) : Omega-3,Maqui Berry Extract

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            DS Biopharma

                            Ireland arrow
                            BioAsia
                            Not Confirmed

                            DS Biopharma

                            Ireland arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3,Omega 6

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Nuvothera

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®

                            Details : Under the terms of the agreement Nuvothera has acquired an option to exclusively licence rights to develop and commercialise EPADILIN® in the United States.

                            Product Name : Epadilin

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 18, 2021

                            Lead Product(s) : Omega-3,Omega 6

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Nuvothera

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Grace Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed

                            Grace Therapeutics

                            U.S.A arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Omega-3

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3

                            Details : Acasti Pharma plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results until calendar Q3, 2020.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 10, 2020

                            Lead Product(s) : Omega-3

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth